Description
The 2020 NHLBI Annual Sickle Cell Disease Research Meeting is a 3-day meeting that provides a forum for investigators, practitioners, and interested health care providers to discuss the progress of ongoing clinical trials, hear presentations about new developments in scientific and clinical aspects of sickle cell disease, and interact with other investigators and NHLBI program staff. This year’s program includes six symposia that cover a broad range of topics.
Three major NHLBI initiatives will be presented at this meeting: The NHLBI Sickle Cell Disease Implementation Consortium, the Cure Sickle Cell Disease Initiative, and the Trans-Omics for Precision Medicine (TOPMed) program.
Agenda
9:00 am - 9:05 am
-
Welcome & Housekeeping
W. Keith Hoots, MD, Director, Division of Blood Diseases & Resources; National Heart, Lung & Blood Institute
9:05 am - 1:00pm
-
SYMPOSIUM 1
9:05 am - 12:00 pm
-
Curative Therapies in Sickle Cell Disease
Lakshmanan Krishnamurti, MD, Section Director of BMT, Chair of Blood and Marrow Transplant, Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta/Emory University
11:00 am - 11:10 am
-
Break
12:00 pm - 1:30 pm
-
BMT for Adults With Sickle Cell Disease: STRIDE Pilot Study
Shannon Smith, Emory University (by Invitation Only)
1:00 pm - 5:00 pm
-
SYMPOSIUM 2
1:00 pm - 2:00 pm
-
The Role of Cannabinoids in Sickle Cell Disease
Session Chairs: Kalpna Gupta, PhD and Susanna Curtis, MD
Medical Marijuana Certification for Adults With Sickle Cell Disease: Observations and Future Directions
Susanna Curtis, MD, Department of Medical Oncology/Hematology, Yale School of Medicine, New Haven, CT
Lessons from the Outcomes of Vaporized Cannabis Trial for Pain in SCD
Kalpna Gupta, PhD, University of California, Irvine, CA
Enhancing Endogenous Cannabinoids to Mitigate Sickle Pathobiology
Donovan Argueta, PhD, University of California Presidential Fellow, Department of Medicine, University of California, Irvine, CA
2:00 pm -3:30 pm
-
DBDR-CURE SCD-NIH-GATES Consortium
W. Keith Hoots, MD, Director, Division of Blood Diseases & Resources- DBDR
Traci Mondoro, PhD, Branch Chief, Division of Blood Diseases & Resources
TopMed Update
Pankaj Qasba, PhD
Program Officer, Division of Blood Diseases & Resources
3:30 pm - 5:00 pm
-
SCDIC Session
Sharon Smith, PhD, Division of Blood Diseases & Resources
3:30 pm - 3:45 pm
-
Overview of the Sickle Cell Disease Implementation Consortium-SCDIC and a Protocol to Improve ED Care using Individualized Pain Plans
Paula Tanabe, PhD, RN, Duke University
3:45 pm - 3:55 pm
-
Early Findings from the Integration of mHealth into the Care of Patients with Sickle Cell Disease to Increase Hydroxyurea Utilization (mESH Study)
Jane Hankins, MD, St. Jude Research Hospital
3:55 pm - 4:05 pm
-
Moving the Needle in Sickle Cell Care: Expert Consensus on What Determines an Unaffiliated Patient;
Andrea Lamont, PhD, Wandersman Center
4:05 pm - 4:20 pm
-
Question & Answer Session
4:20 pm - 4:30 pm
-
Quality of Care Among Adolescents and Adults with SCD in the US: Analysis from the SCDIC
Julie Kanter, MD, University of Alabama
4:30 pm - 4:40 pm
-
Patient Reported Outcomes in the Sickle Cell Disease Implementation Consortium Registry
Marsha Treadwell, PhD, UCSF Benoiff Children’s Hospital Oakland
4:40 pm - 4:50 pm
-
Hydroxyurea is Associated with Miscarriage and Stillbirth
Victor Gordeuk, MD, University of Illinois at Chicago
4:50 pm - 5:00 pm
-
ADJOURN
9:00 am - 1:00 pm
-
SYMPOSIUM 3
9:00 am - 9:10 am
-
Welcome & Housekeeping
Kim Smith-Whitley, MD; Comprehensive Sickle Cell Center for Women & Girls with Blood Disorders-FWGBD
9:10 am - 9:45 am
-
Fertility and Fertility Preservation for Women With SCD
Lydia Pecker, MD, Director, Young Adult Clinic, Johns Hopkins Sickle Cell Ctr.
09:45 am - 10:40 am
-
Contraception
Naomi Tepper, MD, MPH, FACOG; Obstetrician/Gynecologist-CDC
Sarah O’Brien, MD, Pediatric Hematologist, Nationwide Children’s Hospital
10:40 am - 11:00 am
-
Summary Unified - Interactive/Integrated
Kim Smith-Whitley, MD; Director, Comprehensive Sickle Cell Center for Women & Girls with Blood Disorders-FWGBD
11:00 am - 11:10 am
-
Break
11:10 am - 12:10 pm
-
SCD-CARRE
Mark T. Gladwin, MD; Jack D. Myers Distinguished Professor & Chair
Chairman of the Department of Medicine; UPMC and the University of Pittsburgh School of Medicine
Darrell J. Triulzi, MD; Director, Division of Transfusion Medicine Dep. of Pathology University of Pittsburgh; Medical Director, Clinical Service Vitalant, Northeast Division
12:10 pm - 1:00 pm
-
Heymolysis & Immune Complications in SCD
Karina Yazdanbakhsh, PhD; Head of Laboratory, Member, New York Blood Center
1:00 pm - 1:10 pm
-
Break
1:10 pm - 5:00 pm
-
SYMPOSIUM 4
1:10 pm - 2:10 pm
-
Reviewing the Results
DISPLACE- Dissemination and Implementation of Stroke Prevention Looking at the Care Environment
Julie Kanter, MD, University of Alabama at Birmingham School of Medicine
2:10 pm - 5:00 pm
-
SCAPN- Sickle Cell Adult Provider Network
Clinician-Investigator and Staff Hematologist, Red Blood Cell Disorders Program, Therapeutic Apheresis Program, Division of Medical Oncology and Hematology, Department of Medicine, University Health Network
Assistant Professor, Division of Hematology, Department of Medicine, University of Toronto
Joy Ogunsile, MD
Assistant Professor, Division of Hematology & Oncology, Department of Medicine, UAB, Birmingham, AL
9:00 am - 9:05 am
-
WELCOME & HOUSEKEEPING
Wally R. Smith, MD, Florence Neal Cooper Smith Professor of Sickle Cell Disease, Vice Chair for Research, Division of General Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA
9:00 am - 12:00 pm
-
SYMPOSIUM 5
9:05 am - 9:35 am
-
Essential Features of Sickle Cell Centers: Summary of the Evidence & a Consensus
Julie Kanter, MD, Director, Adult Sickle Cell Clinic; University of Alabama Birmingham; First Author, Blood Advances ADV-2020-001743R1 -- Accepted for Publication; Q&A 10 mins
9:35 am - 10:30 am
-
Essential Features of Sickle Cell Centers: Summary of the Evidence & a Consensus
Modupe Idowu, MD Comprehensive Sickle Cell Center, University of Texas, Houston
Farzana Sayani, MC MSc; Director; Penn Comprehensive Sickle Cell Program, University of Pennsylvania
Hannah Lichtsinn, MD; Assistant Professor of Medicine and Pediatrics, HealthPartners, University of Minnesota
10:30 am - 10:45 am
-
Break
10:45 am - 11:45 am
-
Getting Administrative Buy-In & Writing a Business Plan
Patricia Engblom, MHA, FACHE, The Johns Hopkins Hospital
Janis Bozzo, MSN, RN, Yale New Haven Health
11:45 am - 12:45 pm
-
COVID-19 Telemedicine & Re-Imaging the Adult Care Model (TBD)
Julie Kanter, MD
Wally R. Smith, MD VCU
Ify Osunkwo, MD, Director, Sickle Cell Disease Enterprise and Professor of Medicine Levine Cancer Institute Atrium Health, Charlotte, NC
Sophie Lanzkron MD, MHS, Professor of Medicine and Oncology Johns Hopkins School of Medicine; Baltimore, MD
12:45 pm - 1:00 pm
-
Break
1:00 pm - 3:30 pm
-
SYMPOSIUM 6
1:00 pm - 1:20 pm
-
ASH Sickle Cell Initiative
Charles S. Abrams, MD; Professor, Director; Penn-CHOP Blood Center for Patient Care & Discovery, University of Pennsylvania School of Medicine
1:20 pm - 1:40 pm
-
Quantification of Cerebral Metabolic Rate of Oxygen (CMRO2) in SCD
Wenbo Li, MD, Assistant Professor, Johns Hopkins School of Medicine
2:00 pm - 2:20 pm
-
Protection Against Vaso-Occlusion With Daily Dosing of HBI-002, a Low Dose Oral Carbon Monoxide Formulation, In Sickle Cell Disease Mouse Models.
Authors/co-Authors: Edward Gomperts, MD, Howard Levy, MD, Mark Young, PhD: Hillhurst Biopharmaceuticals, Inc.
Fuad Abdulla, MSc; Chunsheng Chen, PhD; Greg Vercellotti, MD; John Belcher, PhD: Division of Hematology, Oncology and Transplantation University of Minnesota Department of Medicine, Vascular Research Center
2:20 pm - 2:30 pm
-
The Many Facets of KYC for Improving Vascular Function in SCD
Kirkwood A. Pritchard, Jr., PhD, Professor, Medical College of Wisconsin
2:30 pm - 2:45 pm
-
Ketamine and Novel Approached to Pain Management in the Sickle Cell Patient With Acute Pain
Steve Long, MD
2:45 pm - 3:00 pm
-
Ketamine and Novel Approached to Pain Management in the Sickle Cell Patient With Acute Pain
Steve Long, MD
3:00 pm - 3:15 pm
-
Intensive Training Program for Multidisciplinary Health Providers in Adult Sickle Cell Disease
Ward Hagar, MD
3:15 pm - 3:30 pm
-
Novel Laboratory Techniques To Determine Red Cell Health And Complication Risk In Patients Receiving Experimental Therapy
Frans Kuypers, PhD
3:30 pm - 3:45 pm
-
Iron Dysregulation in Sickle Cell Disease and its Clinical Effects and Management
Ash Lal, MD